Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05599191 · ClinicalTrials.gov registry record · Phase 3
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
A Phase 3 study of Cough and Refractory Chronic Cough, sponsored by Bellus Health Inc. - a GSK company.
- Active
- Registry status
- Phase 3
- Development phase
- 825
- Enrollment target
- 20
- Study locations
NCT05599191: Active Phase 3 study of Cough and Refractory Chronic Cough, sponsored by Bellus Health Inc. - a GSK company.
NCT05599191 is a Phase 3 study of Cough and Refractory Chronic Cough that is active but no longer recruiting, run by Bellus Health Inc. - a GSK company. The registered enrollment target is 825 participants, above the 153-participant average among 12 other Cough trials with a reported enrollment target (439% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05599191, a Phase 3 study of Cough and Refractory Chronic Cough, is active but no longer recruiting, sponsored by Bellus Health Inc. - a GSK company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 825 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Primary Outcome
Assessed using an ambulatory cough monitor
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BLU-5937
Study Locations (20)
Florida
- GSK Investigational Site - Clearwater
- GSK Investigational Site - Gainesville
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
- GSK Investigational Site - Orlando
California
- GSK Investigational Site - Encinitas
- GSK Investigational Site - Mission Viejo
- GSK Investigational Site - Paramount
- GSK Investigational Site - Roseville
Arizona
- GSK Investigational Site - Litchfield Park
- GSK Investigational Site - Scottsdale
Colorado
- GSK Investigational Site - Aurora
- GSK Investigational Site - Colorado Springs
Illinois
- GSK Investigational Site - Normal
- GSK Investigational Site - Oak Lawn
Iowa
- GSK Investigational Site - Ames
- GSK Investigational Site - Iowa City
Georgia
- GSK Investigational Site - Lawrenceville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 825 participants |
| Start Date | 2022-10-25 |
| Est. Completion | 2026-05-28 |
| Phase | Phase 3 |
What the registry record for NCT05599191 still lists
NCT05599191 is an interventional study that assigns participants to a tested intervention. The registered 825 participants enrollment target is mid-sized for trials with a published cap, above the 153-participant average among 12 other Cough trials with a reported enrollment target (439% higher).
The record links to 2 conditions, with Cough appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05599191 names 20 study sites across 7 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05599191 about?
NCT05599191 is a clinical study titled "A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough". This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
What is the current status of trial NCT05599191?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 825 participants. The study started on 2022-10-25. Estimated completion is 2026-05-28.
What conditions does trial NCT05599191 study?
This clinical trial studies the following conditions: Cough, Refractory Chronic Cough.
What interventions are being tested in trial NCT05599191?
The interventions under investigation include: Placebo (DRUG), BLU-5937 (DRUG).
Who is sponsoring clinical trial NCT05599191?
This trial is sponsored by Bellus Health Inc. - a GSK company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05599191 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cough
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05599191's enrollment target sits among peer trials
825 2nd of 12 the highest of 12 other Cough trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cough trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
RECRUITING · Phase 3
-
Office-Based Superior Laryngeal Nerve Block for Treatment of Neurogenic Cough
RECRUITING
-
The Mechanism Versus PPI Trial
RECRUITING · Phase 4
-
Stimulation of the Larynx to Treat Unexplained Chronic Cough
RECRUITING · NA
-
Work of Breathing Assessment in Triage Scale
ACTIVE NOT RECRUITING
-
Stimulation With Wire Leads to Restore Cough
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05630482 · 825 participants · NA
Randomized Trial of Healthy Family Foundations
- NCT06097728 · 825 participants · Phase 3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
- NCT07102641 · 825 participants · Phase 4
Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies
- NCT07318077 · 825 participants · NA
Radicle GI Health DBG: A Study Assessing the Impact of Health and Wellness Products on GI Health and Related Health Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI